**EPILEPSY**

**FP37**

**BONE HEALTH SCREENING PRACTICES AMONGST BOSTON CHILDREN’S HOSPITAL NEUROLOGISTS: FOLLOW UP ON A QUALITY IMPROVEMENT PROJECT**


**Aim:** Pediatric epilepsy patients are at risk for osteopenia and fractures. Risk factors include being non-ambulatory, decreased sun exposure and reduced vitamin D levels from antiepileptic medications. Prior studies suggest that neurologists do not routinely screen for bone health when treating epilepsy patients. We surveyed paediatric neurologists at our centre on bone health care in paediatric epilepsy patients.

**Methods:** Baseline practices of paediatric neurologists with respect to bone health in epilepsy patients was assessed by surveying all neurologists in our centre. An intervention including education and developing a standardized screening and treatment protocol was implemented. Chart review to evaluate effectiveness was performed one and six months post intervention.

**Results:** Our survey showed that 67% of providers estimated that they screen for bone health <25% of the time. An algorithm was developed to standardize screening and treatment in our centre and all members of the division were educated. After six months of the intervention, Vitamin D levels were checked in 19.5% of epilepsy patients during routine clinic appointments, compared to 2.4% before the intervention, and 12.4% one month after intervention. Six months post intervention, 23% of patients were on vitamin D supplementation of at least 400 International Units.

**Conclusions:** At baseline, the majority of paediatric neurologists at BCH did not routinely screen for bone health in paediatric epilepsy patients. Findings prompted us to develop a standardized screening and treatment algorithm in order to improve awareness and patient care. Follow up chart reviews suggest improved screening and prescription practices after our intervention.

**FP38**

**CLINICAL, EEG AND IMAGING CHARACTERISTICS OF CHILDREN WITH STURGE-WEBER SYNDROME: A PROSPECTIVE, LONGITUDINAL STUDY**

Csaba Juhasz, Eish Asano, Michael E. Rehen, William C. Gay, Otto Muzik, Harry T. Chugani. Departments of Paediatrics and Neurology, Wayne State University, Children’s Hospital of Michigan, United States.

**Introduction:** Reliable markers of neuro-cognitive progression during the clinical course of Sturge-Weber syndrome (SWS) have not been established. In this prospective, longitudinal clinical research study of children with SWS, we have correlated the electro-clinical features, imaging characteristics and cognitive functions (IQ) in a single-center cohort.

**Methods:** Gender, age, scalp EEG abnormalities (background attenuation, slowing, spike frequency), and extent of brain involvement on MRI were correlated with epilepsy variables and IQ in SWS children at baseline (n=65, 63 unilateral, 2 bilateral; mean age: 3.9 years, 3 months – 12.7 years) and at follow up (n=38, mean follow up: 2.3 years). Results: Girls (n=47) were younger (2.7 vs. 5.8 years, p<0.001), had earlier seizure onset (mean: 0.9 vs. 2.1 years, p=0.015) and shorter epilepsy duration (1.9 vs. 3.5 years, p=0.015) than boys, extent of brain involvement, seizure frequency and IQ showed no gender differences. Initial mean IQ was 80±20, and lower initial IQ was associated with EEG background abnormalities and extensive brain involvement (p<0.01). Lower IQ at follow-up was associated with initial EEG background abnormalities (p<0.001) and high spike frequency (p<0.003) but not extent of brain involvement. Interictal spikes were present in 20 patients but were lateralized to the unaffected hemisphere in 6 (30%).

**Conclusions:** EEG background abnormalities and high spike frequency are better predictors of poor cognitive outcome in young SWS children than the extent of brain involvement on MRI; however, interictal spikes may often be falsely lateralizing. The observed gender differences in epilepsy characteristics warrant further studies in larger SWS cohorts.

**FP39**

**HIGH PREVALENCE OF AUTOANTIBODIES TO N-METHYL-D-ASPARTATE RECEPTOR AND THE EFFICACY OF GLUCOCORTICOIDS IN PCDH19-RELATED FEMALE-LIMITED EPILEPSY**

Norimichi Higurashi1, Yukitoshi Takahashi2, Shinichi Hirose1. 1Department of Paediatrics, Jikei University School of Medicine, 2Central Research Institute for the Pathomechanisms of Epilepsy, Fukuoka University, 3National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders.

**Introduction:** A genetic abnormality in PCDH19 causes infantile-onset intractable epilepsy in females (i.e., PCDH19-related female-limited epilepsy, PCDH19-FLE). This condition is characterized by recurrent seizure clusters often involving limbic structures and frequently precipitated by febrile illness. Autoantibodies to N-methyl-D-aspartate receptor (NMDAR-Abs) cause limbic encephalitis, but also appear in some patients with epilepsy, suggesting a possible link between NMDAR-Abs-mediated inflammatory processes and the pathogenesis of the epilepsy.

**Methods:** To examine whether such immune processes are involved in PCDH19-FLE, NMDAR-Abs in the serum and/or cerebrospinal fluid (CSF) were analysed in 8 Japanese patients by using an enzyme-linked immunosorbent assay or immunoblotting assay. Glucocorticoid treatment efficacy was also evaluated in 4 patients.

**Results:** Titers of NMDAR-Abs taken within 6 years of disease onset were significantly elevated in the serum of 7/8 patients (87.5%) and in the CSF of 4/6 patients (66.7%). However, in a follow-up evaluation of 3 patients, serum titers were reduced. Although seizures were refractory to anticonvulsants, glucocorticoids immediately suppressed ongoing seizure clusters in all 4 patients who received them, specifically, 10-30 mg/kg of intravenous methylprednisolone for 3 days was effective in 3 patients aged 3 years or younger, and 1 mg/kg oral prednisolone was effective in 1 patient aged 11 years.

**Discussion:** The prevalence of NMDAR-Abs was extremely high in patients with PCDH19-FLE, particularly during the early disease stages. Although the clinical significance of NMDAR-Abs remains unclear, the immediate anticonvulsant efficacity of glucocorticoid treatment suggests that increased vulnerability of the blood–brain barrier to systemic inflammation might underlie PCDH19-FLE pathogenesis.

**FP40**

**AUTISTIC CHILDREN WITH EEG ABNORMALITIES AND/OR EPILEPSY: CLINICAL CHARACTERIZATION IN TWO INDEPENDENT SAMPLES**

Roberto Saccò1, Silvia Giovinnazzo2, Paolo Curatolo1, Antonio M. Persico3. 1Child and Adolescent Neuropsychiatry Unit, University Campus Bio-medico, Rome, 2Child Neuropsychiatry Unit, University “Tor Vergata”, Rome.

**Introduction:** Several studies have reported a high frequency of epilepsy and/or co-occurrence of EEG abnormalities in children with autism spectrum disorder, although the incidence rates vary between 5% to 46%.

**Methods:** We analysed two different samples of non-syndromic ASD patients: an original sample encompassing 432 Italian patients and a replica sample including 714 Caucasian American patients recruited by the Autism Genetic Resource Exchange Consortium. Comparable clinical, biological and developmental variables were correlated in both samples with “presence/absence of epilepsy” or “presence/absence of EEG abnormalities”, and tested for association between each variable and biological endophenotypes by non-parametric Kendall τ and Kruskal-Wallis ANOVA.

**Results:** In the experimental sample and in the replica sample, ASD patients positive for EEG abnormalities display a significant association with a lower risk of familial history for autoimmune/allergic diseases (Italian and AGRE sample: τ=-0.115 and -0.252, respectively; both P<0.05) and those affected by epilepsy are characterized specifically by verbal language delay in the absence of a generalized neurodevelopmental delay (Italian and AGRE sample: τ= 0.100 and 0.073; both p<0.05). Interestingly, Italian patients with EEG abnormalities show significantly lower serotonin blood levels (τ=0.183; P<0.01).

**Conclusions:** These results extend previous findings, by supporting a deleterious effect of EEG abnormalities on verbal language...
development, and by pointing toward a protective role against the development of epilepsy for a family history of autoimmune/allergic diseases and elevated serum skin blood levels.

**FP41**

**CLINICAL MARKERS OF POSTICTAL GENERALIZED EEG SUPPRESSION (PGES) IN CHILDREN**

Elizabeth Kozmutcha, Kazuo Okanari, Hiroshi Otsuka, Elizabeth J Donner. Division of Neurology, The Hospital for Sick Children, Canada.

**Aim:** Postictal generalized EEG suppression (PGES) has been proposed as a neurophysiological marker for sudden unexpected death in epilepsy (SUDEP). If PGES is a marker of potentially fatal seizures, it is critical to identify clinical features that distinguish people with epilepsy that are prone to PGES.

**Methods:** A retrospective review of vEEG at the Hospital for Sick Children (2009-2011) was performed, to identify episodes of PGES as defined by Surges et al, 2011, along with clinical features of paediatric patients at the time of PGES recording.

**Results:** 26 children (62%, 16 male) demonstrated 49 seizures with PGES (37%) from a total of 134 seizures. Duration of PGES ranged 2.5-4 sec (mean 30 sec). 42 of 48 seizures associated with PGES were generalized tonic clonic seizures (GTCS). Duration of 42 PGES with GTCS (mean 35 sec) was significantly longer than that of 6 PGES without GTCS (mean 9.6 sec; p < 0.005). Longer PGES duration significantly correlated with lower E-Chess score, a marker of epilepsy severity (R = 0.63, p < 0.001) and with less lifetime use of AEDs (R = 0.40, p < 0.05). 8 children had global developmental delay (31%) and had a shorter PGES duration (mean 17.7 sec) compared to those children with normal development (mean 37.7 sec; p < 0.005).

**Conclusion:** Longer duration of PGES in children significantly correlates with GTCS, lower E-Chess score, less lifetime use of AEDs and normal development. The latter three findings suggest that PGES is more common in pediatric patients with less severe epilepsy.

**FP42**

**WHO ARE THE SUPER RESPONDERS TO THE KETOGENIC DIET?**

Janak Nathan. Shushrusha Hospital, Ranade Road, Dadar W, Mumbai, India

**Introduction:** The ketogenic diet (KD) is mainly used in pharmaco-resistant epilepsy. However, some seem to respond dramatically to the KD while others take several months to years to have complete cessation of the seizures.

**Methods:** A retrospective study was done of all those who responded with complete cessation of seizures in less than four weeks (super responders) in all our patients since 1996. We looked at the impact of age, seizure type, seizure syndrome, duration of seizures prior to institution of the KD and keto ratio.

**Results:** Of a total of 205 patients (ages from 4 months to 57 years), 11 patients were super-responders. Of these 8 patients had symptomatic epileptic encephalopathy, 2 had localization related epilepsy with lesion. Except for two, the rest (9) had their first seizure before the age of one year. KD was responded with complete cessation of seizures in less than four weeks (super responders) in all our patients since 1996. We looked at the impact of age, seizure type, seizure syndrome, duration of seizures prior to institution of the KD and keto ratio.

**Conclusion:** Super responders are usually younger in age and those put on KD earlier. Epileptic encephalopathy seems to respond better. Individual keto ratio is not significant. Most other authors too have found the same results.

**FP43**

**SUCCESSFUL USE OF FENFLURAMINE AS ADD-ON TREATMENT IN DRAVET SYNDROME: A THREE YEARS PROSPECTIVE FOLLOW-UP**

Berten Ceulemans 1, 2. Lieven Lagae 1, 3. 1Epilepsy Centre for Children and Youth, Pudlerbos, Belgium. 2University Hospital Antwerp, University of Antwerp Belgium. 3University Hospital Leuven, University of Leuven, Belgium

**Purpose:** Evaluation of efficacy of fenfluramine as an add-on anti-epileptic drug in Dravet syndrome.

**Methods:** Dravet syndrome remains, notwithstanding the introduction of newer anti-epileptic drugs, a therapy resistant and catastrophic epilepsy syndrome.

Fenfluramine is an amphetamine-like drug often used in the past as part of anti-obesity treatment. Because of possible cardiac side effects (valve thickening, pulmonary hypertension), it has been withdrawn from the market in the US and Europe. In Belgium, it was allowed to study its potential anti-convulsive effect in a small group of well-defined patients with Dravet syndrome.

**Results:** Twelve patients, seven girls and five boys, with a genetically proven (11/12) diagnosis of Dravet syndrome received add-on therapy with fenfluramine.

The retrospective data were published in 2012 (Ceulemans et al, Epilepsia 2012 Jul; 53(7):1131-9). We now present the results of 3 years prospective follow-up of ten patients of this group, including two new patients. Children were carefully monitored for reduction of seizure frequency and cardiac side effects. Mean age ranged from 3 - 35 years. Dosage of fenfluramine was 0.34 (0.12-0.90) mg/kg/d. All patients had at least a >75% of reduction of seizures in the study period of 3 years. Eight out of twelve were seizure free for at least one year. Three were seizure free for the complete trial period. In four patients a mild thickening of 1 or 2 cardiac valves, without clinical significance, was seen. The mitral valve seems to be the most frequently damaged valve. Only one patient had valve thickening on each ultrasound cardiac examination. Loss of appetite (4 patients) seems not a major problem.

**Conclusions:** These new prospective data confirm the promising results from the long-term retrospective study of fenfluramine as add-on anti epileptic medication in Dravet syndrome. Eight out of twelve patients (66%) remained seizure free for at least for one year. The mitral valve seems to be the most vulnerable for valve thickening by this drug. Realising that this observational study has limitations, a larger prospective study is under way, now the drug has recently been granted as orphan drug designation in Europe and the US.

**FP44**

**USEFULNESS OF VIDEO-EEG MONITORING IN CHILDREN**

Betiana G Comas, Nicolas Espinoza, Manina Abearbury, Brenda Giagante, Clarisa Mait, Maria Vaccarezza, Guillermo Agosta, Walter Silva. Hospital Italiano de Buenos Aires.

**Aim:** To analyse the sensitivity of the v-EEG for detecting clinical events and analyse therapeutic changes after the reading.

**Method:** A retrospective, descriptive study of 178 paediatric v-EEGs recordings at the Hospital Italiano de Buenos Aires from January 2011 to February 2012. The V-EEG were divided in: With epileptic clinical events, with nonepileptic clinical events and Uneventful. We analysed the therapeutic changes. The data were analysed using univariate statistics.

**Results:** Age: was 1 month to 17 years (median 9.1). Clinical events were recorded in 120/178 (67.4%), 81/178 (45.5%), were Epileptic and 39/178 (21.4%) non-epileptic. The sensitivity of the v-EEG divided by duration was: 6 h 71.2%, 24 h 68.9% and 48 h or more 78%. According to the age distribution, the sensitivity was 69.8% in pre-schoolers, 58.97% in school and 82.14% in adolescents. The sensitivity for detection of clinical events was better in 6 hrs. v-EEG in pre-schoolers (p < 0.05) and in 48 hrs. v-EEG in all ages (p < 0.05). The therapeutic approach was changed in 72/178 (40.4%). AEDs were indicated in 9.75%, AEDs were modified in 63.9%, AEDs were suspended in 2.75%, epilepsy surgery was indicated in 9.75%, were referred to mental service health 9.75% and ketogenic diet was indicated or suspended in 4.1%.

**Conclusion:** The v-EEG was useful for the detection of clinical events in two thirds of the patients and the sensitivity was higher in those that lasted two days or more. The modification of AEDs was the most frequent therapeutic change.

**FP45**

**TRAJECTORIES OF HEALTH AND WELL-BEING IN CHILDREN WITH EPILEPSY: HYPOTHESES AND METHODOLOGY OF A CANADIAN LONGITUDINAL STUDY**

Gabriel Ronen. McMaster University, Hamilton, Ontario, Canada

**Aim:** Our study quantifies direct, mediating and moderating influences of various epilepsy, co-morbids, child, and family variables on children’s health and well-being over the early life-course. We will present hypotheses and methodology of this prospective longitudinal study based on a conceptual framework for understanding health outcomes.
Methods: The population is children with epilepsy 8-14 years old and their caregivers from across Canada. Children, caregivers, and health professionals complete 17 measures at five visits over 28 months. The measures are all based on content, the source of the items, psychometric properties, and provision for child self-report. Our cross-sectional and longitudinal design includes a relational model for structural equation modelling of specific biomedical and psychosocial variables with hierarchical direction of influence. We use hierarchical linear modelling to measure change over time.

Results: Demographics: among 506 families: mean child age 11.4 years; epilepsy onset 6.2 years, epilepsy duration 5.2 years; and mean IQ 99.4. Characteristics: 71% take a single medication, 46% have experienced medication failure, 29% have been seizure free, 31% had low and 37% high seizure severity over the previous year.

Conclusion: Discussion of these perspectives will help researchers consider their methodology and encourage longitudinal studies. Furthermore, our experience may help clinicians identify what to look for when evaluating outcomes research. We believe that the next generation of research to understand life-course effects on the lives of children and youth with chronic conditions and their families must occur over real time.

FP48
THE ASSOCIATION OF FEBRILE SEIZURE AND SINGLE NUCLEOTIDE POLYMORPHISM OF CYCOXYGENASE-2
Kun-Long Hung 1, Hui-Ju Chen 1, Jinn-Shyan Wang 2, Jyh-Feng Lu 2. Department of Pediatrics, Cathay General Hospital, Taipei, Taiwan; School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan

Introduction: Febrile seizure (FS) is the most common form of childhood convulsions with an estimated prevalence of 2-5% among children less than 5 years of age. Several polymorphisms have been suggested to be associated with FS including SCN1A, IL-1, IL-1Ra, IL-10... etc. Due to the febrile nature of the disease, possible association of FS and selected single nucleotide polymorphism (SNP) in the cyclooxygenase-2 (COX-2) gene was thus investigated in this study.

Method: A series of FS patients were collected consecutively at one medical centre: IL-1Ra and IL-10 polymorphisms, as well as 9 SNPs in the COX-2 gene were analysed by direct DNA sequencing and restriction endonuclease digestion. The frequencies of SNPs were compared to that of apparent health individuals.

Results: The IL-Ra intron 2 variable tandem repeat polymorphisms did not exhibit significant polymorphic characteristics among analysed FS (n=15) and health individuals (n=10). Both groups carry the predominant allele I. The frequency of IL-10 SNP (rs1800624) also did not exhibit significant difference between two groups. However, a significant difference in frequency was observed in one (rs689466) out of nine analysed COX-2 SNPs. This -1192 A allele exhibits significant higher frequency in FS (70%) than that of health (15%) group (p<0.05).

Conclusion: An apparent association between the -1192 A allele in the COX-2 gene and FS is observed. This novel evidence demonstrates the possible role of COX-2 SNP in the pathogenesis of the specific epileptic syndrome FS.

FP49
INFANTILE SPASMS: ICTAL VIDEO-EEG CLASSIFICATION BASED ON THE DELPHI WEST GROUP PROPOSAL
Marina Abarstury, Betiana Comas, Nicolas Espinosa, Fernando Rios Pistoia, Guillermo Agosta, Walter Silva. Hospital Italiano Buenos Aires, Argentina

Introduction: The West Delphi group proposed a classification of infantile spasms (IS): IS in cluster with Hypsarrhythmia (West syndrome), IS in cluster without hypsarrhythmia, IS single-spasms variant (ISSV) with hypsarrhythmia and ISSV without hypsarrhythmia.

Aim: To classify the IS registered in the video EEGs according to the Delphi West group proposal and analyse outcome.

Methods: Observational retrospective study including 33 video-EEGs, between January 2010 and September 2013.

Results: median age 6.1 months, 19 (57.5%) were female. According to the classification, we observed: 14 (42.4%) had West syndrome (WS), 10 (30.3%) IS in cluster without hypsarrhythmia, 7 (21.2%) ISSV with hypsarrhythmia, and 2 (6%) ISSV without hypsarrhythmia. 24 patients had symptomatic epilepsy and 7 cryptogenic. EEG findings: 18 (63.6%) presented hypsarrhythmia, 24 (81.8%) multifocal paroxysms and 6 unifocal paroxysms. Fourteen of the 18 (77.7%) patients with hypsarrhythmia, had symptomatic epilepsy.

We analysed 31 patients. 8 (25.8%), were preterm. 23 (74, 2%) had a normal neurological exam before seizures started, 13 (49.4%) worsened developmental delay. One patient died. The median duration of IS was 4 months (IQR 1, 5-9), 4 months in patients with hypsarrhythmia and 6.5 months, without hypsarrhythmia.

Outcome: 13 developed refractory epilepsy, 10/13 had symptomatic epilepsy and IF/13 had hypsarrhythmia.

12 of 17 (70, 5%) patients with hypsarrhythmia and 3/12 (25%) patients without hypsarrhythmia lost developmental skills. (p=0.01).
Conclusions: We observed a high frequency of patients with West syndrome and ISSV without hypsarrhythmia. Patients with or without hypsarrhythmia developed refractory epilepsy associated to developmental delay, being more frequent in patients with hypsarrhythmia.